
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded capsule containing topiramate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing topiramate are listed in capsule, tablet and solution forms.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Topiramate is an anticonvulsant (seizure medicine) also used to prevent migraine that a pharmacy may compound when a prescriber orders it.
Topiramate is a second-generation antiepileptic drug. Its exact mechanism is not known, but it blocks sodium channels in nerve cells, strengthens the calming neurotransmitter GABA, blocks certain glutamate receptors and weakly inhibits the enzyme carbonic anhydrase, which together are thought to steady overactive brain signaling. Manufactured products include Topamax tablets and sprinkle capsules, Eprontia oral solution, and Trokendi XR and Qudexy XR extended-release capsules. Topamax is indicated as monotherapy or add-on therapy for partial-onset or primary generalized tonic-clonic seizures, as add-on therapy for seizures of Lennox-Gastaut syndrome, and for migraine prevention in patients 12 and older. Qsymia combines topiramate with phentermine for chronic weight management. A prescriber might order topiramate compounded in a strength or form that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Topiramate labels carry no boxed warning. Warnings include sudden nearsightedness with angle-closure glaucoma and visual field loss, reduced sweating with overheating (mostly in children), metabolic acidosis, kidney stones, suicidal thoughts, slowed thinking and word-finding trouble, high ammonia levels (especially with valproic acid), and serious allergic reactions, including severe skin rashes, a multiorgan reaction called DRESS, anaphylaxis and angioedema. Tell your prescriber right away about any rash. Topiramate can harm an unborn baby, including cleft lip and palate. It may make hormonal birth control less reliable, and phenytoin and carbamazepine lower its levels. Do not use it if you have had an allergic reaction to it. MedlinePlus advises drinking plenty of fluids and, with extended-release capsules, avoiding alcohol for 6 hours before and after a dose. LactMed notes low infant levels and occasional sedation or diarrhea, so watch a breastfed baby. Do not stop it suddenly, and talk to your prescriber or pharmacist about side effects.
Topiramate blocks voltage-dependent sodium channels, augments GABA-A activity at some receptor subtypes, antagonizes AMPA/kainate glutamate receptors and inhibits carbonic anhydrase isozymes II and IV. Per the Topamax label, absorption is rapid with peak levels at about 2 hours, relative bioavailability of the tablet is about 80%, and food has no effect. Protein binding is 15% to 41%, metabolism is limited, about 70% is excreted unchanged in urine, and mean half-life is 21 hours. Clearance falls in moderate to severe renal impairment, and topiramate is removed by hemodialysis. Labeled indications: Topamax and Eprontia for epilepsy (age 2 and older) and migraine prevention (12 and older). StatPearls lists off-label uses, including alcohol use disorder, binge eating disorder, essential tremor and neuropathic pain, which are not FDA-approved indications for topiramate alone. The label reports an increased risk of oral clefts and small-for-gestational-age infants after in utero exposure. Contraceptive efficacy may fall even when bleeding patterns do not change. Discontinue at the first sign of rash unless clearly not drug-related; DRESS, SJS/TEN, anaphylaxis and angioedema have been reported. Dosing is per prescriber; renal impairment requires adjustment. Monitor serum bicarbonate, renal stone risk, vision, mood and, with valproate, ammonia. Withdraw gradually.
Swallow each capsule whole with a glass of water, unless your label says otherwise. Do not crush, chew or open the capsule unless your pharmacist tells you it is safe to do so. Take it at the times shown on your prescription label. If you miss a dose or are unsure how to take it, call the pharmacy.
Capsules are nonaqueous, so under USP <795> they usually carry a beyond-use date of up to 180 days when no other stability data apply. Keep the vial tightly closed at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard any capsules left after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth